Ann Thor
Concepts (453)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 72 | 2023 | 2249 | 4.270 |
Why?
| | Receptor, ErbB-2 | 28 | 2020 | 342 | 3.070 |
Why?
| | Metformin | 10 | 2018 | 328 | 2.120 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 7 | 2024 | 77 | 1.890 |
Why?
| | Testicular Neoplasms | 7 | 2024 | 110 | 1.860 |
Why?
| | Tamoxifen | 11 | 2023 | 202 | 1.700 |
Why?
| | Receptors, Estrogen | 17 | 2020 | 435 | 1.550 |
Why?
| | Thyroid Hormones | 2 | 2023 | 61 | 1.500 |
Why?
| | Receptor, ErbB-3 | 8 | 2016 | 44 | 1.300 |
Why?
| | Biomarkers, Tumor | 17 | 2024 | 1279 | 1.300 |
Why?
| | Lymphatic Metastasis | 18 | 2024 | 351 | 1.250 |
Why?
| | Cell Proliferation | 16 | 2023 | 2482 | 1.240 |
Why?
| | Genes, erbB-2 | 8 | 2013 | 28 | 1.100 |
Why?
| | Cell Cycle | 5 | 2023 | 604 | 1.080 |
Why?
| | Mammary Neoplasms, Experimental | 6 | 2017 | 68 | 1.050 |
Why?
| | Lymph Node Excision | 5 | 2024 | 174 | 0.970 |
Why?
| | MicroRNAs | 6 | 2024 | 704 | 0.920 |
Why?
| | Estrogen Receptor alpha | 3 | 2023 | 144 | 0.900 |
Why?
| | Apoptosis | 21 | 2018 | 2557 | 0.880 |
Why?
| | Estrogens | 2 | 2023 | 361 | 0.800 |
Why?
| | Cell Line, Tumor | 23 | 2023 | 3420 | 0.800 |
Why?
| | ErbB Receptors | 6 | 2010 | 616 | 0.670 |
Why?
| | Up-Regulation | 3 | 2020 | 846 | 0.660 |
Why?
| | Hormone Replacement Therapy | 1 | 2020 | 98 | 0.640 |
Why?
| | Immunohistochemistry | 26 | 2020 | 1740 | 0.610 |
Why?
| | Mammary Neoplasms, Animal | 3 | 2018 | 33 | 0.600 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2016 | 202 | 0.600 |
Why?
| | Disease-Free Survival | 11 | 2020 | 690 | 0.580 |
Why?
| | Caspases | 5 | 2009 | 247 | 0.570 |
Why?
| | Tumor Suppressor Protein p53 | 14 | 2011 | 531 | 0.540 |
Why?
| | Prognosis | 21 | 2020 | 4031 | 0.500 |
Why?
| | Gene Expression Regulation, Neoplastic | 18 | 2021 | 1402 | 0.500 |
Why?
| | Antineoplastic Agents | 10 | 2018 | 2145 | 0.500 |
Why?
| | Claudins | 1 | 2016 | 25 | 0.490 |
Why?
| | Drug Resistance, Neoplasm | 10 | 2023 | 806 | 0.490 |
Why?
| | Receptor, IGF Type 1 | 3 | 2016 | 65 | 0.480 |
Why?
| | Trastuzumab | 8 | 2016 | 101 | 0.460 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2015 | 1695 | 0.450 |
Why?
| | Transcriptome | 1 | 2020 | 974 | 0.440 |
Why?
| | Carcinogenesis | 1 | 2016 | 220 | 0.430 |
Why?
| | Carcinoma, Ductal, Breast | 5 | 2002 | 83 | 0.430 |
Why?
| | Signal Transduction | 16 | 2023 | 5096 | 0.430 |
Why?
| | Seminoma | 2 | 2024 | 20 | 0.430 |
Why?
| | Estradiol | 2 | 2009 | 513 | 0.410 |
Why?
| | Genistein | 2 | 2010 | 13 | 0.400 |
Why?
| | Hypoglycemic Agents | 3 | 2017 | 1285 | 0.400 |
Why?
| | Receptors, Steroid | 2 | 2012 | 50 | 0.400 |
Why?
| | Doxorubicin | 10 | 2011 | 368 | 0.380 |
Why?
| | Female | 68 | 2023 | 73162 | 0.380 |
Why?
| | Humans | 93 | 2024 | 137514 | 0.370 |
Why?
| | Antineoplastic Agents, Hormonal | 5 | 2020 | 161 | 0.370 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2012 | 94 | 0.360 |
Why?
| | Receptors, Progesterone | 6 | 2020 | 349 | 0.340 |
Why?
| | Teratoma | 2 | 2022 | 114 | 0.340 |
Why?
| | STAT3 Transcription Factor | 1 | 2012 | 208 | 0.330 |
Why?
| | Neoplasm Staging | 9 | 2024 | 1377 | 0.330 |
Why?
| | Neoplasm Invasiveness | 7 | 2016 | 510 | 0.330 |
Why?
| | Genes, p53 | 5 | 2000 | 72 | 0.330 |
Why?
| | Mice | 18 | 2023 | 17843 | 0.320 |
Why?
| | Neoplasm Proteins | 5 | 2016 | 433 | 0.300 |
Why?
| | Glucose | 1 | 2013 | 1018 | 0.290 |
Why?
| | Glycoproteins | 2 | 2005 | 345 | 0.280 |
Why?
| | Retroperitoneal Space | 2 | 2024 | 20 | 0.280 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2010 | 455 | 0.280 |
Why?
| | Mammary Tumor Virus, Mouse | 2 | 2004 | 44 | 0.270 |
Why?
| | Mice, Transgenic | 8 | 2018 | 2182 | 0.270 |
Why?
| | MCF-7 Cells | 4 | 2020 | 127 | 0.260 |
Why?
| | Animals | 23 | 2023 | 37011 | 0.260 |
Why?
| | Neoplasm, Residual | 2 | 2024 | 133 | 0.250 |
Why?
| | Carcinoma | 4 | 1995 | 237 | 0.250 |
Why?
| | Antibodies, Monoclonal | 7 | 2013 | 1428 | 0.250 |
Why?
| | Bromodeoxyuridine | 2 | 1999 | 80 | 0.240 |
Why?
| | Predictive Value of Tests | 6 | 2024 | 2039 | 0.240 |
Why?
| | Protein Kinase Inhibitors | 3 | 2016 | 920 | 0.240 |
Why?
| | Multivariate Analysis | 8 | 2005 | 1524 | 0.230 |
Why?
| | Polymerase Chain Reaction | 6 | 2021 | 1061 | 0.230 |
Why?
| | Middle Aged | 31 | 2024 | 33355 | 0.230 |
Why?
| | Radiation Tolerance | 1 | 2005 | 98 | 0.230 |
Why?
| | Tyrosine | 2 | 2007 | 224 | 0.220 |
Why?
| | Enzyme Activation | 4 | 2009 | 816 | 0.220 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 868 | 0.220 |
Why?
| | Quinazolines | 2 | 2016 | 249 | 0.220 |
Why?
| | Cocarcinogenesis | 1 | 2003 | 14 | 0.210 |
Why?
| | Phosphorylation | 5 | 2011 | 1762 | 0.210 |
Why?
| | Survival Analysis | 8 | 2005 | 1320 | 0.210 |
Why?
| | Isoflavones | 1 | 2003 | 26 | 0.210 |
Why?
| | Cell Survival | 5 | 2018 | 1122 | 0.210 |
Why?
| | Paclitaxel | 4 | 2015 | 231 | 0.200 |
Why?
| | Chromosomes | 1 | 2003 | 108 | 0.200 |
Why?
| | Ki-67 Antigen | 4 | 2014 | 112 | 0.190 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2002 | 36 | 0.190 |
Why?
| | Cyclins | 2 | 2000 | 91 | 0.190 |
Why?
| | Gelsolin | 1 | 2001 | 9 | 0.190 |
Why?
| | Chromosome Aberrations | 1 | 2002 | 157 | 0.180 |
Why?
| | Orchiectomy | 1 | 2021 | 71 | 0.180 |
Why?
| | Cyclophosphamide | 7 | 2011 | 251 | 0.180 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 25 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-ets | 2 | 2020 | 56 | 0.180 |
Why?
| | Breast | 4 | 2018 | 153 | 0.180 |
Why?
| | Caspase 3 | 4 | 2006 | 246 | 0.170 |
Why?
| | Rats | 7 | 2022 | 5676 | 0.170 |
Why?
| | Diet | 3 | 2018 | 1273 | 0.170 |
Why?
| | Etoposide | 1 | 2001 | 157 | 0.170 |
Why?
| | DNA-Binding Proteins | 3 | 2020 | 1507 | 0.170 |
Why?
| | Obesity | 4 | 2022 | 2974 | 0.170 |
Why?
| | Cell Division | 6 | 2005 | 795 | 0.170 |
Why?
| | Neoplastic Stem Cells | 2 | 2014 | 398 | 0.160 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2011 | 366 | 0.160 |
Why?
| | Mice, SCID | 1 | 2020 | 367 | 0.160 |
Why?
| | TOR Serine-Threonine Kinases | 3 | 2012 | 414 | 0.160 |
Why?
| | Transcription Factors | 3 | 2020 | 1717 | 0.160 |
Why?
| | Drug Screening Assays, Antitumor | 3 | 2016 | 196 | 0.160 |
Why?
| | Proto-Oncogene Proteins | 5 | 2008 | 646 | 0.160 |
Why?
| | Prospective Studies | 4 | 2024 | 7598 | 0.160 |
Why?
| | Carcinoma, Papillary | 1 | 1999 | 81 | 0.160 |
Why?
| | Mitotic Index | 1 | 1999 | 26 | 0.160 |
Why?
| | Mice, Inbred NOD | 1 | 2020 | 601 | 0.150 |
Why?
| | Receptors, Androgen | 2 | 2017 | 149 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2015 | 392 | 0.150 |
Why?
| | Adult | 20 | 2024 | 37821 | 0.150 |
Why?
| | Ovarian Neoplasms | 4 | 1995 | 563 | 0.150 |
Why?
| | Aromatase | 1 | 2018 | 32 | 0.150 |
Why?
| | Drug Synergism | 3 | 2018 | 379 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 892 | 0.140 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 53 | 0.140 |
Why?
| | Tumor Cells, Cultured | 6 | 2009 | 957 | 0.140 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2018 | 47 | 0.140 |
Why?
| | Phenylthiohydantoin | 2 | 2017 | 42 | 0.140 |
Why?
| | Antigens, Neoplasm | 2 | 2009 | 322 | 0.140 |
Why?
| | Autism Spectrum Disorder | 1 | 2023 | 400 | 0.140 |
Why?
| | Down-Regulation | 3 | 2010 | 658 | 0.140 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2008 | 319 | 0.140 |
Why?
| | Ovariectomy | 4 | 2022 | 150 | 0.140 |
Why?
| | Fluorouracil | 5 | 2009 | 213 | 0.140 |
Why?
| | Tumor Burden | 4 | 2022 | 311 | 0.140 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2009 | 99 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2013 | 807 | 0.130 |
Why?
| | Postmenopause | 5 | 2022 | 361 | 0.130 |
Why?
| | Organic Cation Transport Proteins | 1 | 2017 | 30 | 0.130 |
Why?
| | Triazoles | 1 | 2018 | 151 | 0.130 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 235 | 0.130 |
Why?
| | Smad Proteins | 1 | 2016 | 42 | 0.120 |
Why?
| | Cathepsin D | 2 | 2002 | 18 | 0.120 |
Why?
| | Gene Knock-In Techniques | 1 | 2016 | 56 | 0.120 |
Why?
| | Calcitriol | 1 | 2016 | 58 | 0.120 |
Why?
| | Antibiotics, Antineoplastic | 3 | 2009 | 130 | 0.120 |
Why?
| | Ovary | 1 | 2017 | 218 | 0.120 |
Why?
| | Proteins | 2 | 1992 | 1012 | 0.120 |
Why?
| | Gene Amplification | 2 | 2009 | 109 | 0.110 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2016 | 171 | 0.110 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.110 |
Why?
| | Immunoradiometric Assay | 1 | 1994 | 2 | 0.110 |
Why?
| | Mental Disorders | 1 | 2023 | 1083 | 0.110 |
Why?
| | Immunoprecipitation | 2 | 2011 | 155 | 0.110 |
Why?
| | Young Adult | 4 | 2024 | 13243 | 0.110 |
Why?
| | Androgen Receptor Antagonists | 1 | 2014 | 34 | 0.110 |
Why?
| | Disease Progression | 6 | 2018 | 2755 | 0.110 |
Why?
| | Postpartum Period | 2 | 2014 | 341 | 0.110 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2016 | 316 | 0.100 |
Why?
| | Mice, Knockout | 1 | 2020 | 3020 | 0.100 |
Why?
| | Androgen Antagonists | 1 | 2014 | 82 | 0.100 |
Why?
| | Receptor, ErbB-4 | 2 | 2010 | 19 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2010 | 75 | 0.100 |
Why?
| | Transforming Growth Factor beta | 1 | 2016 | 480 | 0.100 |
Why?
| | Adenocarcinoma | 3 | 2012 | 937 | 0.100 |
Why?
| | Blotting, Western | 3 | 2011 | 1227 | 0.100 |
Why?
| | Vitamin D | 1 | 2016 | 393 | 0.100 |
Why?
| | Overnutrition | 1 | 2012 | 30 | 0.100 |
Why?
| | Sweden | 2 | 2024 | 101 | 0.100 |
Why?
| | Nucleic Acid Hybridization | 2 | 2003 | 190 | 0.100 |
Why?
| | Aminosalicylic Acids | 1 | 2012 | 5 | 0.100 |
Why?
| | DNA, Neoplasm | 6 | 2005 | 165 | 0.100 |
Why?
| | Benzenesulfonates | 1 | 2012 | 22 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2007 | 234 | 0.090 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 1992 | 56 | 0.090 |
Why?
| | Chromones | 1 | 2011 | 44 | 0.090 |
Why?
| | Gene Expression Profiling | 2 | 2016 | 1770 | 0.090 |
Why?
| | RNA, Messenger | 4 | 2016 | 2838 | 0.090 |
Why?
| | Genital Diseases, Female | 1 | 1991 | 27 | 0.090 |
Why?
| | Disease Models, Animal | 4 | 2017 | 4295 | 0.090 |
Why?
| | Dasatinib | 1 | 2011 | 54 | 0.090 |
Why?
| | Fluoxymesterone | 1 | 1991 | 2 | 0.090 |
Why?
| | Proportional Hazards Models | 4 | 2005 | 1263 | 0.090 |
Why?
| | Thiazoles | 1 | 2011 | 123 | 0.090 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2012 | 188 | 0.090 |
Why?
| | Aged | 14 | 2015 | 23798 | 0.090 |
Why?
| | S Phase | 2 | 2010 | 78 | 0.090 |
Why?
| | Mitosis | 3 | 2001 | 193 | 0.090 |
Why?
| | Morpholines | 1 | 2011 | 126 | 0.090 |
Why?
| | Reagent Kits, Diagnostic | 1 | 1991 | 44 | 0.090 |
Why?
| | Cohort Studies | 2 | 2020 | 5730 | 0.090 |
Why?
| | Weight Gain | 3 | 2022 | 518 | 0.080 |
Why?
| | Genital Neoplasms, Female | 1 | 1991 | 88 | 0.080 |
Why?
| | Chromosomes, Human, Pair 17 | 3 | 2002 | 55 | 0.080 |
Why?
| | Proto-Oncogenes | 1 | 1989 | 29 | 0.080 |
Why?
| | Neoplasm Metastasis | 5 | 2005 | 659 | 0.080 |
Why?
| | Radioisotopes | 1 | 1989 | 31 | 0.080 |
Why?
| | Flow Cytometry | 3 | 2007 | 1185 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 2066 | 0.080 |
Why?
| | Aged, 80 and over | 6 | 2002 | 7593 | 0.080 |
Why?
| | Anthracyclines | 1 | 2009 | 49 | 0.080 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2009 | 45 | 0.080 |
Why?
| | Follow-Up Studies | 5 | 2020 | 5139 | 0.080 |
Why?
| | Male | 7 | 2024 | 67718 | 0.070 |
Why?
| | Gene Deletion | 2 | 2002 | 393 | 0.070 |
Why?
| | Treatment Outcome | 5 | 2007 | 10821 | 0.070 |
Why?
| | Pyrimidines | 1 | 2011 | 472 | 0.070 |
Why?
| | RNA, Small Interfering | 2 | 2007 | 621 | 0.070 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2009 | 197 | 0.070 |
Why?
| | MAP Kinase Signaling System | 1 | 2010 | 322 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 974 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2014 | 1099 | 0.070 |
Why?
| | Mice, Nude | 1 | 2009 | 696 | 0.070 |
Why?
| | Gene Dosage | 1 | 2008 | 148 | 0.070 |
Why?
| | Mutation | 3 | 1995 | 3964 | 0.070 |
Why?
| | Reproducibility of Results | 3 | 2023 | 3292 | 0.070 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 869 | 0.070 |
Why?
| | Immunoenzyme Techniques | 3 | 1999 | 219 | 0.070 |
Why?
| | Time Factors | 4 | 2015 | 6817 | 0.070 |
Why?
| | Energy Metabolism | 1 | 2012 | 895 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2016 | 437 | 0.060 |
Why?
| | Enzyme Precursors | 1 | 2006 | 15 | 0.060 |
Why?
| | Aging | 4 | 2003 | 1866 | 0.060 |
Why?
| | Cell Nucleus | 4 | 2006 | 615 | 0.060 |
Why?
| | Receptor, Notch1 | 1 | 2006 | 64 | 0.060 |
Why?
| | Multigene Family | 2 | 2003 | 202 | 0.060 |
Why?
| | Lamin Type B | 1 | 2005 | 7 | 0.060 |
Why?
| | Mitochondria | 3 | 2008 | 947 | 0.060 |
Why?
| | Herpes Simplex | 1 | 2006 | 93 | 0.060 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 660 | 0.060 |
Why?
| | Survival Rate | 4 | 2020 | 1980 | 0.060 |
Why?
| | Herpesvirus 1, Human | 1 | 2006 | 86 | 0.060 |
Why?
| | Cell Nucleolus | 1 | 2005 | 17 | 0.060 |
Why?
| | Age Factors | 3 | 2003 | 3301 | 0.060 |
Why?
| | Nitriles | 2 | 2017 | 175 | 0.060 |
Why?
| | Benzamides | 2 | 2017 | 218 | 0.060 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 121 | 0.060 |
Why?
| | Feedback | 1 | 2005 | 174 | 0.060 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2007 | 190 | 0.060 |
Why?
| | RNA Interference | 3 | 2015 | 464 | 0.060 |
Why?
| | Protein Kinases | 1 | 2006 | 319 | 0.050 |
Why?
| | Tacrolimus Binding Protein 1A | 1 | 2003 | 10 | 0.050 |
Why?
| | Tumor Microenvironment | 2 | 2018 | 682 | 0.050 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2003 | 28 | 0.050 |
Why?
| | Rats, Wistar | 2 | 2017 | 457 | 0.050 |
Why?
| | Mice, Inbred Strains | 1 | 2004 | 413 | 0.050 |
Why?
| | Adipose Tissue | 2 | 2018 | 624 | 0.050 |
Why?
| | Estrogens, Non-Steroidal | 1 | 2003 | 10 | 0.050 |
Why?
| | Genes, Tumor Suppressor | 1 | 2003 | 86 | 0.050 |
Why?
| | Phytoestrogens | 1 | 2003 | 17 | 0.050 |
Why?
| | Estrogen Antagonists | 1 | 2003 | 45 | 0.050 |
Why?
| | Plant Preparations | 1 | 2003 | 34 | 0.050 |
Why?
| | Actins | 1 | 2005 | 416 | 0.050 |
Why?
| | Cell Line | 2 | 2003 | 2852 | 0.050 |
Why?
| | Chromosome Banding | 1 | 2002 | 19 | 0.050 |
Why?
| | Anticarcinogenic Agents | 1 | 2003 | 77 | 0.050 |
Why?
| | Chromosomes, Human, Pair 16 | 1 | 2002 | 36 | 0.050 |
Why?
| | Embryoid Bodies | 1 | 2022 | 8 | 0.050 |
Why?
| | Mammary Glands, Animal | 1 | 2003 | 129 | 0.050 |
Why?
| | Rodentia | 1 | 2022 | 57 | 0.050 |
Why?
| | 3' Untranslated Regions | 2 | 2014 | 145 | 0.050 |
Why?
| | Transfection | 3 | 2015 | 948 | 0.050 |
Why?
| | Trefoil Factor-1 | 2 | 1992 | 2 | 0.050 |
Why?
| | alpha-Fetoproteins | 1 | 2021 | 46 | 0.050 |
Why?
| | Fallopian Tubes | 2 | 1991 | 31 | 0.050 |
Why?
| | In Situ Nick-End Labeling | 1 | 2001 | 124 | 0.040 |
Why?
| | Chorionic Gonadotropin | 1 | 2021 | 80 | 0.040 |
Why?
| | Nuclear Proteins | 2 | 2000 | 710 | 0.040 |
Why?
| | RNA, Catalytic | 1 | 2002 | 186 | 0.040 |
Why?
| | DNA Fragmentation | 1 | 2001 | 42 | 0.040 |
Why?
| | Plasmids | 1 | 2002 | 363 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2001 | 90 | 0.040 |
Why?
| | Antigens, Nuclear | 1 | 2000 | 18 | 0.040 |
Why?
| | Fibrosis | 1 | 2023 | 552 | 0.040 |
Why?
| | RNA Stability | 1 | 2021 | 117 | 0.040 |
Why?
| | Breast Diseases | 1 | 2000 | 22 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2000 | 190 | 0.040 |
Why?
| | Integrin beta3 | 2 | 2013 | 11 | 0.040 |
Why?
| | Tumor Suppressor Proteins | 2 | 1992 | 328 | 0.040 |
Why?
| | Telomerase | 1 | 2001 | 250 | 0.040 |
Why?
| | N-Glycosyl Hydrolases | 1 | 1998 | 6 | 0.040 |
Why?
| | Methylnitrosourea | 1 | 2018 | 7 | 0.040 |
Why?
| | DNA Glycosylases | 1 | 1998 | 8 | 0.040 |
Why?
| | Antibodies | 1 | 2000 | 414 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2018 | 47 | 0.040 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2018 | 45 | 0.040 |
Why?
| | Trans-Activators | 1 | 2000 | 399 | 0.040 |
Why?
| | Codon | 3 | 1993 | 90 | 0.040 |
Why?
| | Half-Life | 1 | 2018 | 166 | 0.040 |
Why?
| | Stromal Cells | 1 | 2018 | 111 | 0.040 |
Why?
| | NF-kappa B | 1 | 2002 | 694 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2023 | 3546 | 0.040 |
Why?
| | Hyaluronan Receptors | 1 | 1998 | 103 | 0.030 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 182 | 0.030 |
Why?
| | Gene Expression | 3 | 2013 | 1505 | 0.030 |
Why?
| | Organic Cation Transporter 2 | 1 | 2017 | 8 | 0.030 |
Why?
| | Retrospective Studies | 4 | 2005 | 15628 | 0.030 |
Why?
| | Cell Movement | 1 | 2001 | 972 | 0.030 |
Why?
| | Extracellular Matrix Proteins | 1 | 1998 | 153 | 0.030 |
Why?
| | Steroids | 1 | 2017 | 167 | 0.030 |
Why?
| | DNA Repair | 1 | 1998 | 230 | 0.030 |
Why?
| | Antigens, CD | 2 | 2014 | 524 | 0.030 |
Why?
| | Proto-Oncogene Proteins pp60(c-src) | 1 | 2016 | 11 | 0.030 |
Why?
| | Oncogenes | 1 | 2016 | 117 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2015 | 26 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 433 | 0.030 |
Why?
| | Oncogene Proteins | 1 | 1995 | 59 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2014 | 1324 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2018 | 504 | 0.030 |
Why?
| | RNA | 1 | 2001 | 924 | 0.030 |
Why?
| | Tosyl Compounds | 1 | 2014 | 15 | 0.030 |
Why?
| | Mammary Glands, Human | 1 | 2014 | 64 | 0.030 |
Why?
| | Integrin alpha6 | 1 | 2013 | 9 | 0.030 |
Why?
| | Adolescent | 3 | 2024 | 21555 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 2014 | 87 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2015 | 285 | 0.030 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 62 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2017 | 741 | 0.030 |
Why?
| | Parity | 1 | 2014 | 126 | 0.030 |
Why?
| | Premenopause | 1 | 2014 | 125 | 0.030 |
Why?
| | Testosterone | 1 | 2017 | 399 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2024 | 2681 | 0.030 |
Why?
| | Anilides | 1 | 2014 | 73 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 195 | 0.030 |
Why?
| | Immunoassay | 1 | 1994 | 114 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 1995 | 301 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 256 | 0.030 |
Why?
| | bcl-2-Associated X Protein | 2 | 2007 | 56 | 0.030 |
Why?
| | Sirolimus | 2 | 2006 | 275 | 0.030 |
Why?
| | Organ Specificity | 1 | 2013 | 304 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2017 | 778 | 0.030 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2013 | 50 | 0.020 |
Why?
| | Lactation | 1 | 2014 | 184 | 0.020 |
Why?
| | Immune System | 1 | 2014 | 177 | 0.020 |
Why?
| | Neoplasms | 2 | 2012 | 2666 | 0.020 |
Why?
| | Lipogenesis | 1 | 2012 | 60 | 0.020 |
Why?
| | Brain Neoplasms | 2 | 1993 | 1241 | 0.020 |
Why?
| | Point Mutation | 1 | 1993 | 234 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 414 | 0.020 |
Why?
| | Broad Ligament | 1 | 1991 | 1 | 0.020 |
Why?
| | Astrocytoma | 1 | 1993 | 128 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 329 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2007 | 1242 | 0.020 |
Why?
| | Peritoneum | 1 | 1991 | 43 | 0.020 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 1991 | 51 | 0.020 |
Why?
| | Mucins | 1 | 1991 | 74 | 0.020 |
Why?
| | Glycolysis | 1 | 2012 | 319 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2010 | 199 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1991 | 177 | 0.020 |
Why?
| | Hormones | 1 | 1991 | 143 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2010 | 318 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1703 | 0.020 |
Why?
| | Soft Tissue Neoplasms | 1 | 1991 | 116 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2013 | 4206 | 0.020 |
Why?
| | Precipitin Tests | 1 | 1989 | 100 | 0.020 |
Why?
| | Pregnancy | 2 | 2014 | 6745 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 1989 | 119 | 0.020 |
Why?
| | Odds Ratio | 1 | 1992 | 1063 | 0.020 |
Why?
| | Glioblastoma | 1 | 1993 | 344 | 0.020 |
Why?
| | Risk Factors | 1 | 2003 | 10356 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2010 | 193 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2010 | 765 | 0.020 |
Why?
| | Lymph Nodes | 1 | 1991 | 493 | 0.020 |
Why?
| | Drug Interactions | 1 | 2009 | 409 | 0.020 |
Why?
| | Cytochromes c | 1 | 2007 | 60 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2007 | 71 | 0.020 |
Why?
| | Apoptotic Protease-Activating Factor 1 | 1 | 2007 | 2 | 0.020 |
Why?
| | Caspase 10 | 1 | 2006 | 5 | 0.020 |
Why?
| | Caspase 2 | 1 | 2006 | 13 | 0.020 |
Why?
| | Caspase 8 | 1 | 2006 | 49 | 0.020 |
Why?
| | Caspase 9 | 1 | 2006 | 57 | 0.020 |
Why?
| | Amino Acid Sequence | 3 | 1998 | 2146 | 0.020 |
Why?
| | Cysteine Endopeptidases | 1 | 2006 | 72 | 0.020 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 14 | 0.020 |
Why?
| | Caspase 7 | 1 | 2006 | 22 | 0.020 |
Why?
| | Eukaryotic Initiation Factor-4E | 1 | 2006 | 27 | 0.020 |
Why?
| | Isoenzymes | 1 | 2007 | 305 | 0.020 |
Why?
| | Vero Cells | 1 | 2006 | 67 | 0.020 |
Why?
| | Cytosol | 1 | 2006 | 227 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4172 | 0.020 |
Why?
| | Base Sequence | 2 | 2003 | 2180 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2010 | 1255 | 0.020 |
Why?
| | Virus Assembly | 1 | 2006 | 77 | 0.010 |
Why?
| | Taxoids | 1 | 2004 | 104 | 0.010 |
Why?
| | Protein Binding | 1 | 2010 | 2229 | 0.010 |
Why?
| | Protein Processing, Post-Translational | 1 | 2006 | 471 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2003 | 269 | 0.010 |
Why?
| | Melanoma, Experimental | 1 | 2003 | 113 | 0.010 |
Why?
| | Americas | 1 | 2002 | 28 | 0.010 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2002 | 29 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 79 | 0.010 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 64 | 0.010 |
Why?
| | Lymphokines | 1 | 2002 | 131 | 0.010 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2002 | 86 | 0.010 |
Why?
| | Platelet Membrane Glycoproteins | 1 | 2002 | 37 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2003 | 467 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2002 | 53 | 0.010 |
Why?
| | Gene Targeting | 1 | 2002 | 83 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2003 | 5792 | 0.010 |
Why?
| | Exons | 2 | 1993 | 349 | 0.010 |
Why?
| | Europe | 1 | 2002 | 414 | 0.010 |
Why?
| | Templates, Genetic | 1 | 2001 | 63 | 0.010 |
Why?
| | Substrate Specificity | 1 | 2002 | 385 | 0.010 |
Why?
| | Molecular Sequence Data | 2 | 1998 | 2901 | 0.010 |
Why?
| | DNA, Superhelical | 1 | 2000 | 11 | 0.010 |
Why?
| | DNA Footprinting | 1 | 2000 | 33 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2002 | 379 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2002 | 352 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2003 | 1271 | 0.010 |
Why?
| | Genes, erbB | 1 | 2000 | 2 | 0.010 |
Why?
| | Ploidies | 1 | 2000 | 18 | 0.010 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2000 | 113 | 0.010 |
Why?
| | Macromolecular Substances | 1 | 2000 | 227 | 0.010 |
Why?
| | Pathology, Clinical | 1 | 2000 | 37 | 0.010 |
Why?
| | Gene Silencing | 1 | 2000 | 195 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2002 | 544 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2000 | 308 | 0.010 |
Why?
| | Forecasting | 1 | 2000 | 386 | 0.010 |
Why?
| | Genetic Therapy | 1 | 2000 | 296 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 2000 | 391 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 2000 | 720 | 0.010 |
Why?
| | Binding Sites | 1 | 2000 | 1310 | 0.010 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 1996 | 15 | 0.010 |
Why?
| | ras Proteins | 1 | 1998 | 151 | 0.010 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 1996 | 50 | 0.010 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1996 | 59 | 0.010 |
Why?
| | Immunoblotting | 1 | 1997 | 307 | 0.010 |
Why?
| | Adenine | 1 | 1998 | 268 | 0.010 |
Why?
| | Societies, Medical | 1 | 2000 | 820 | 0.010 |
Why?
| | Heterozygote | 1 | 1996 | 292 | 0.010 |
Why?
| | Hyaluronic Acid | 1 | 1998 | 223 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 1995 | 26 | 0.010 |
Why?
| | Protein Isoforms | 1 | 1997 | 403 | 0.010 |
Why?
| | Cyclin D1 | 1 | 1995 | 67 | 0.010 |
Why?
| | Melanoma | 1 | 2002 | 758 | 0.010 |
Why?
| | United States | 2 | 2004 | 14696 | 0.010 |
Why?
| | Factor VIII | 1 | 1995 | 99 | 0.010 |
Why?
| | Single-Blind Method | 1 | 1995 | 288 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2000 | 1465 | 0.010 |
Why?
| | Observer Variation | 1 | 1995 | 347 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2000 | 1458 | 0.010 |
Why?
| | Alleles | 1 | 1996 | 891 | 0.010 |
Why?
| | Biopsy | 1 | 1995 | 1132 | 0.010 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1991 | 53 | 0.010 |
Why?
| | Peripheral Nerves | 1 | 1991 | 70 | 0.010 |
Why?
| | Risk Assessment | 1 | 2000 | 3439 | 0.010 |
Why?
| | DNA | 1 | 1996 | 1460 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 1993 | 658 | 0.000 |
Why?
| | Protein Conformation | 1 | 1993 | 930 | 0.000 |
Why?
| | Lung Neoplasms | 1 | 2002 | 2494 | 0.000 |
Why?
| | Cerebral Cortex | 1 | 1991 | 459 | 0.000 |
Why?
| | Glioma | 1 | 1991 | 397 | 0.000 |
Why?
| | Child | 1 | 1993 | 22037 | 0.000 |
Why?
|
|
Thor's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|